20112020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Dr Hellyer is an early career researcher (PhD 2015) with an interest in neuroscience, molecular pharmacology and the genetic basis of disease. Dr Hellyer started his research career in toxinology, studying the mechanism of action of novel marine neurotoxins during his honours and PhD research. He is currently a senior postdoctoral research fellow in the Gregory Laboratory at the Monash Institute of Pharmaceutical Sciences. Dr Hellyer's current research is focused on metabotropic glutamate (mGlu) receptors, their role in neurological disorders (especially schizophrenia) and novel ways to target these receptors in the treatment of CNS disease.

As an emerging independent researcher, Dr Hellyer has a burgeoning interest in naturally occuring mutations in mGlu receptors, and how they contribute to the pathology of neurological disorders such as schizophrenia and spinocerebellar ataxia. Using the skills he has learned in the Gregory Lab, Dr Hellyer hopes to explore the pathophysiological effects of naturally occuring mutations, and their ability to be modulated by small therapeutic molecules.

Dr Hellyer has extensive expertise in multiple molecular pharmacology techniques, mammalian neuronal cell culture and tissue electrophysiology. Additionally, Dr Hellyer has strong written communication sklls, having worked for 1 year in medical communications after being awarded his PhD. Both his written and research skills are evidenced by 12 publications, including 10 first author articles. These include such highlights as:

1) the first description of a nicotinic antagonist mechanism of action for marine pinnatoxins E, F and G

2) evidence of context dependent mGlu desensitisation in response to modulation by small molecule drug-like compounds

3) 2 papers showing for the first time the structural basis of mGlu5 pharmacological phenomena such as bias and probe dependence

Research interests

BROAD:

1) neuroscience

2) molecular pharmacology

3) natural product research

 

SPECIFIC:

- identifying the mechanism of action of novel natural products and their potential utilisation as therapeutics

- allosteric modulaton of GPCRs as a therapeutic approach in CNS disorders

- genetic basis of schizophrenia and spinocerebellar ataxia, in particular mutations in mGlu receptors

- molecular basis of mGlu desensitisation and regulation

Education/Academic qualification

Pharmacology, PhD, University of Otago

Award Date: 1 May 2015

Research area keywords

  • metabotropic glutamate receptor
  • neuroscience
  • Drug Discovery
  • Biased Signalling

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism

Sengmany, K., Hellyer, S. D., Christopoulos, A., Lapinsky, D. J., Leach, K. & Gregory, K. J., 5 May 2020, (Accepted/In press) In : Biochemical Pharmacology. 15 p., 114011.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Identification of monellin as the first naturally derived proteinaceous allosteric agonist of metabotropic glutamate receptor 5

Chen, A. N. Y., Hellyer, S. D., Trinh, P. N. H., Leach, K. & Gregory, K. J., Jun 2020, In : Basic & Clinical Pharmacology & Toxicology. 126, S6, p. 104-115 12 p.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology

Sengmany, K., Hellyer, S. D., Albold, S., Wang, T., Conn, P. J., May, L. T., Christopoulos, A., Leach, K. & Gregory, K. J., 1 May 2019, In : Neuropharmacology. 149, p. 83-96 14 p.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Metabotropic glutamate receptor 5 (mGlu5)-positive allosteric modulators differentially induce or potentiate desensitization of mGlu5 signaling in recombinant cells and neurons

Hellyer, S. D., Albold, S., Sengmany, K., Singh, J., Leach, K. & Gregory, K. J., 1 Jan 2019, In : Journal of Neurochemistry. 151, 3, p. 301-315 15 p.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

“Selective” class C G protein-coupled receptor modulators are neutral or biased mGlu5 allosteric ligands

Hellyer, S. D., Albold, S., Wang, T., Chen, A. N. Y., May, L. T., Leach, K. & Gregory, K. J., 1 May 2018, In : Molecular Pharmacology. 93, 5, p. 504-514 11 p.

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Prizes

ASPET Highlighted Trainee Author

Hellyer, Shane (Recipient), 2018

Prize: Prize (including medals and awards)